Safe Accelerated Venetoclax Escalation in CLL

Summary

This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely tolerate an accelerated, daily venetoclax dose ramp-up rather than the standard approved schedule (5-week dose ramp-up). The name of the study drug involved in this study is: * Venetoclax The following drugs may also be included in some participants treatment regimen: * Obinutuzumab * Rituximab

Timeline

Start

2021-04-14

Primary completion

2025-06-02

Completion

2030-06-02

Publications

• Crombie JL, Ahn IE, Ren Y, Tyekucheva S, Carey C, Kniezewski M, Normilus S, Solomon S, Montegaard J, Kim AI, Merryman RW, Armand P, Fisher DC, Brown JR, Davids MS. SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL. Blood Adv. 2026 Jun 23:bloodadvances.2026020392. doi: 10.1182/bloodadvances.2026020392. Online ahead of print.

Drugs

Indications